Moderna Outlines Strategic Moves at J.P. Morgan Healthcare Conference

Moderna reported reaching product sales of $3.0 to $3.1 billion for 2024 with an ending cash balance near $9.5 billion. Looking ahead, the company anticipates 2025 revenue of $1.5 to $2.5 billion and plans to cut cash costs by $1 billion. This is part of a broader strategy for further $0.5 billion reductions in 2026, aiming to conclude 2025 with $6 billion in cash.

Key milestones predicted for 2025 include up to three regulatory approvals and six significant data readouts. The focus remains on a prioritized portfolio addressing various health needs like respiratory viruses and rare diseases. In 2024, notably, the RSV vaccine received approval. The company's strategic goals include driving sales growth and product approvals while reducing costs.

Moderna's pipeline advances include a Phase 3 COVID-19 vaccine and ongoing trials in oncology and rare diseases.